Kindred Biosciences, Inc. (KIN) Stock Is An 52-Week High Flier

June 14, 2018 - By Jeanette Kaplan

Kindred Biosciences, Inc. (NASDAQ:KIN) Logo

Investors sentiment decreased to 0.78 in 2018 Q1. Its down 0.15, from 0.93 in 2017Q4. It dropped, as 6 investors sold Kindred Biosciences, Inc. shares while 21 reduced holdings. 9 funds opened positions while 12 raised stakes. 16.83 million shares or 3.46% less from 17.44 million shares in 2017Q4 were reported.
Jpmorgan Chase accumulated 0% or 5,121 shares. California State Teachers Retirement Sys, California-based fund reported 38,744 shares. New York State Common Retirement Fund has 243,249 shares for 0% of their portfolio. Morgan Stanley holds 0.01% or 2.16M shares in its portfolio. Blackrock owns 1.10M shares. Connor Clark Lunn Limited has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 75,775 shares. Rhumbline Advisers reported 22,765 shares. Royal Financial Bank Of Canada invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Moreover, State Bank Of America De has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 22,600 shares. Voya Investment Management Limited Liability has invested 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). Jacobs Levy Equity Mngmt stated it has 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Tiaa Cref Mgmt, New York-based fund reported 61,427 shares. Bancorp Of Ny Mellon Corporation owns 88,163 shares or 0% of their US portfolio. Dimensional Fund Advsrs L P reported 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Citigroup Incorporated holds 31,007 shares or 0% of its portfolio.

Since January 2, 2018, it had 0 insider buys, and 9 sales for $1.04 million activity. $60,660 worth of Kindred Biosciences, Inc. (NASDAQ:KIN) shares were sold by Townsend Raymond.

The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) hit a new 52-week high and has $11.86 target or 4.00 % above today’s $11.40 share price. The 9 months bullish chart indicates low risk for the $321.52M company. The 1-year high was reported on Jun, 14 by Barchart.com. If the $11.86 price target is reached, the company will be worth $12.86M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 5.07% or $0.55 during the last trading session, reaching $11.4. About 78,452 shares traded. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 39.72% since June 14, 2017 and is uptrending. It has outperformed by 27.15% the S&P500.

Analysts await Kindred Biosciences, Inc. (NASDAQ:KIN) to report earnings on August, 6. They expect $-0.38 EPS, down 31.03 % or $0.09 from last year’s $-0.29 per share. After $-0.36 actual EPS reported by Kindred Biosciences, Inc. for the previous quarter, Wall Street now forecasts 5.56 % negative EPS growth.

Kindred Biosciences, Inc. (NASDAQ:KIN) Ratings Coverage

Among 3 analysts covering Kindred Biosciences (NASDAQ:KIN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Kindred Biosciences had 4 analyst reports since December 27, 2017 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, May 9. C.L. King initiated the shares of KIN in report on Wednesday, December 27 with “Hold” rating. On Monday, February 26 the stock rating was initiated by FBR Capital with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Friday, March 2 report.

More recent Kindred Biosciences, Inc. (NASDAQ:KIN) news were published by: Seekingalpha.com which released: “KindredBio announces positive results from KIND-014 for the treatment of gastric ulcers in horses” on May 30, 2018. Also Prnewswire.com published the news titled: “Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational …” on May 29, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO” with publication date: June 01, 2018 was also an interesting one.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $321.52 million. The companyÂ’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: